Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38beta2, respectively. Adezmapimod inhibits LCK, GSK3beta and PKBalpha with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator[1][2][3].
Molecular Weight:
377.43
Purity:
99.96
CAS Number:
[152121-47-6]
Formula:
C21H16FN3OS
Target:
Autophagy,HSP,Mitophagy,Organoid,p38 MAPK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
